Cargando…
Use of microspheres in embolization for unruptured renal angiomyolipomas
PURPOSE: To describe our initial experience with use of microspheres in transcatheter arterial embolization (TAE) for unruptured sporadic renal angiomyolipomas (AMLs). MATERIALS AND METHODS: Seven consecutive patients with seven unruptured sporadic renal AMLs, 6 females and 1 male, with a median age...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060982/ https://www.ncbi.nlm.nih.gov/pubmed/33977148 http://dx.doi.org/10.1515/med-2021-0280 |
_version_ | 1783681472946765824 |
---|---|
author | Shimohira, Masashi Nagai, Keiichi Ohta, Kengo Sawada, Yusuke Naiki, Taku Nagai, Takashi Yasui, Takahiro Shibamoto, Yuta |
author_facet | Shimohira, Masashi Nagai, Keiichi Ohta, Kengo Sawada, Yusuke Naiki, Taku Nagai, Takashi Yasui, Takahiro Shibamoto, Yuta |
author_sort | Shimohira, Masashi |
collection | PubMed |
description | PURPOSE: To describe our initial experience with use of microspheres in transcatheter arterial embolization (TAE) for unruptured sporadic renal angiomyolipomas (AMLs). MATERIALS AND METHODS: Seven consecutive patients with seven unruptured sporadic renal AMLs, 6 females and 1 male, with a median age of 45 years (range, 30–69 years), underwent TAE using microspheres between November 2016 and February 2020. We evaluated the technical success rate, complications related to the procedure, clinical success rate, and the shrinkage rate of renal AML. Technical success was defined as the completion of TAE. Clinical success was defined as presence of shrinkage of the renal AML after TAE. RESULTS: In all patients, TAE using microspheres was accomplished and technical success rate was 100% (7/7). Three patients exhibited slight pain, but it improved with only observation, and the minor complication rate was 43% (3/7) and major complication rate was 0% (0/7). After the TAE, shrinkage of renal AML was confirmed in 6 of 7 patients, and clinical success rate was 86% (6/7). The median of shrinkage rate was 47% (range, 26–83%) with a median follow-up period of 19 months (range, 4–30 months). CONCLUSION: TAE using microspheres appears to be effective and safe for unruptured sporadic renal AMLs. |
format | Online Article Text |
id | pubmed-8060982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | De Gruyter |
record_format | MEDLINE/PubMed |
spelling | pubmed-80609822021-05-10 Use of microspheres in embolization for unruptured renal angiomyolipomas Shimohira, Masashi Nagai, Keiichi Ohta, Kengo Sawada, Yusuke Naiki, Taku Nagai, Takashi Yasui, Takahiro Shibamoto, Yuta Open Med (Wars) Communication PURPOSE: To describe our initial experience with use of microspheres in transcatheter arterial embolization (TAE) for unruptured sporadic renal angiomyolipomas (AMLs). MATERIALS AND METHODS: Seven consecutive patients with seven unruptured sporadic renal AMLs, 6 females and 1 male, with a median age of 45 years (range, 30–69 years), underwent TAE using microspheres between November 2016 and February 2020. We evaluated the technical success rate, complications related to the procedure, clinical success rate, and the shrinkage rate of renal AML. Technical success was defined as the completion of TAE. Clinical success was defined as presence of shrinkage of the renal AML after TAE. RESULTS: In all patients, TAE using microspheres was accomplished and technical success rate was 100% (7/7). Three patients exhibited slight pain, but it improved with only observation, and the minor complication rate was 43% (3/7) and major complication rate was 0% (0/7). After the TAE, shrinkage of renal AML was confirmed in 6 of 7 patients, and clinical success rate was 86% (6/7). The median of shrinkage rate was 47% (range, 26–83%) with a median follow-up period of 19 months (range, 4–30 months). CONCLUSION: TAE using microspheres appears to be effective and safe for unruptured sporadic renal AMLs. De Gruyter 2021-04-20 /pmc/articles/PMC8060982/ /pubmed/33977148 http://dx.doi.org/10.1515/med-2021-0280 Text en © 2021 Masashi Shimohira et al., published by De Gruyter https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. |
spellingShingle | Communication Shimohira, Masashi Nagai, Keiichi Ohta, Kengo Sawada, Yusuke Naiki, Taku Nagai, Takashi Yasui, Takahiro Shibamoto, Yuta Use of microspheres in embolization for unruptured renal angiomyolipomas |
title | Use of microspheres in embolization for unruptured renal angiomyolipomas |
title_full | Use of microspheres in embolization for unruptured renal angiomyolipomas |
title_fullStr | Use of microspheres in embolization for unruptured renal angiomyolipomas |
title_full_unstemmed | Use of microspheres in embolization for unruptured renal angiomyolipomas |
title_short | Use of microspheres in embolization for unruptured renal angiomyolipomas |
title_sort | use of microspheres in embolization for unruptured renal angiomyolipomas |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060982/ https://www.ncbi.nlm.nih.gov/pubmed/33977148 http://dx.doi.org/10.1515/med-2021-0280 |
work_keys_str_mv | AT shimohiramasashi useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas AT nagaikeiichi useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas AT ohtakengo useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas AT sawadayusuke useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas AT naikitaku useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas AT nagaitakashi useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas AT yasuitakahiro useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas AT shibamotoyuta useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas |